FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* STAAB THOMAS R II				BI	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX]										tionship of Report all applicable) Director Officer (give title		10% C			
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 06/05/2015									Λ	Seni	w) ior Vice Pr		elow) d CF		
(Street) DURHA (City)			27703 Zip)		4. If	Ameno	dment,	Date o	of Origin	al File	d (Month/Da	ay/Yea	ar)		. Indiv ine) X	Forn	or Joint/Group In filed by One In filed by Mor Ison	e Reporting	Perso	on
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					Execution Date,					es Acquired (A) o Of (D) (Instr. 3, 4 a			and 5) Secu Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	ect rect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A (D) or)	Price		Transa	action(s) 3 and 4)			(111511.4)
Common Stock ⁽¹⁾ 06				06/05/	5/2015				S		6,000		D	\$12.75(2)		5 ⁽²⁾ 153,144		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E		4. Transa Code (8)		5. Nui of Derivi Secui Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired sed	6. Date Expirat (Month	ion Da		Amo Secu Und Deri	4) A	mount			9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Indi (I) (Inst	(D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2015.
- 2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$12.50 to \$13.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote

/s/ Alane P. Barnes, by power of attorney

06/09/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.